Understanding how genetics affect warfarin dosing in Hispanic and Latino patients
Pharmacogenomics of Warfarin in Hispanics and Latinos
This study is trying to see how genetics affect the right dose of warfarin for Hispanic and Latino patients to make their treatment safer and more effective.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Arizona Academic / other |
| Locations | 1 site (Tucson, Arizona) |
| Trial ID | NCT02972385 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the pharmacogenomics of warfarin, a commonly used blood thinner, specifically in Hispanic and Latino populations. It aims to identify genetic variations that influence the required dosage of warfarin, as current dosing algorithms are primarily based on Caucasian populations and may not be accurate for non-Caucasian individuals. Participants will provide DNA samples through cheek swabs or blood draws during routine clinical visits, and their warfarin dose requirements will be analyzed using linear regression methods. The goal is to improve the safety and effectiveness of warfarin therapy for these populations.
Who should consider this trial
Good fit: Ideal candidates for this study are Hispanic or Latino individuals aged 18 and older who are currently receiving warfarin therapy.
Not a fit: Patients who are under 18 years old or have severe hepatic impairment will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate warfarin dosing for Hispanic and Latino patients, reducing the risks of thrombosis and hemorrhage.
How similar studies have performed: Other studies have shown success in pharmacogenomic approaches to warfarin dosing, but this specific focus on Hispanic and Latino populations is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years of age * Ability to give informed consent * Therapeutic INR for at least 2 consecutive clinic visits * Self-identifies as Hispanic or Latino Exclusion Criteria: * Less than 18 years old * Unable to give informed consent * Severe hepatic impairment
Where this trial is running
Tucson, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona, United States (Recruiting)
Study contacts
- Study coordinator: Jason H Karnes, PharmD, PhD
- Email: karnes@pharmacy.arizona.edu
- Phone: 520-626-1447
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.